Novel role of puberty onset protein kisspeptin as an anticoagulation peptide

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 1, 2011, Pages 40-49

  Qureshi, Irfan Zia ^a   Kanwal, Sobia ^a  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

anticoagulants; bleeding tendency; heparin; kisspeptin; metastin; puberty onset protein

Indexed keywords

CALCIUM; HEPARIN; KISSPEPTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBOCYTE COUNT; THROMBOCYTE VOLUME;

ANIMALS; ANTICOAGULANTS; BLEEDING TIME; BLOOD COAGULATION; CALCIUM; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROTHROMBIN TIME; RATS; RATS, SPRAGUE-DAWLEY; TUMOR SUPPRESSOR PROTEINS;

EID: 78650796696     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328340e6a7     Document Type: Article

References (54)

1. Mead EJ, Maguire JJ, Kuc RE, Davenport AP. Kisspeptins: A multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. Br J Pharmacol 2007; 151:1143-1153.
2. Tena-Sempere M. Kisspeptin signaling in the brain: Recent developments and future challenges. Mol Cell Endocrinol 2010; 314:164-169.
3. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weismann BE, et al. KiSS-1, a novel malignant melanoma metastasis-supressor gene. J Natl Cancer Inst 1996; 88:1731-1737.
4. Makri A, Pissimissis N, Lembessis, Polychronakos C, Koutsilieris M. The kisspeptin (KII-1/GPR54) system in cancer biology. Cancer Treatment Rev 2008; 34:682-692.
5. Tena-Sempere M. GPR54 and kisspeptin in reproduction. Hum Reprod Update 2006; 12:631-639.
6. Harms JF, Welch DR, Miele ME. KISS1 metastasis suppression and emergent pathways. Clin Exp Metastasis 2003; 20:11-18.
7. Kotani M, Detheux M, Vandenbogaerde A, Communi D, vanderwinden Jm LE, Poul E, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptin, the natural ligands of the orphan G protein coupled receptor GPR54. J Biol Chem 2001; 276:34631-34636.
8. Cabrera-Vera TM, Vanhauwe J, Thomas TO, Medkova M, Preininger A, Mazzoni MR, et al. Insights intoGprotein structure, function, and regulation. Endocr Rev 2003; 24:765-781.
9. Castaño JP, Martínez-Fuentes AJ, Gutiérrez-Pascual E, Vaudry H, Tena- Sempere M, Malagón MM. Intracellular signaling pathways activated by kisspeptins through GPR54: do multiple signals underlie function diversity? Peptides 2009; 30:10-15.
10. Navenot JM, Fujii N, Peiper SC. KiSS1 metastasis suppressor gene product induces suppression of tyrosine kinase receptor signaling to Akt, tumor necrosis factor family ligand expression, and apoptosis. Mol Pharmacol 2009; 75:1074-1083.
11. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003; 349:1614-1627.
12. Colledge WH. GPR54 and kisspeptins. Results Probl Cell Differ 2008; 46:117-143.
13. Roa J, García-Galiano D, Castellano JM, Gaytan F, Pinilla L, Tena-Sempere M. Metabolic control of puberty onset: new players, new mechanisms. Mol Cell Endocrinol 2009; 21 [Epub ahead of print].
14. Nijher GK, Dhillo WS, Bloom SR. Kisspeptin: A novel role in the regulation of reproductive function. Drug News Perspect 2009; 22:573-578.
15. Plant TM. Hypothalamic control of the pituitary-gonadal axis in higher primates: Key advances over the last two decades. J Neuroendocrinol 2008; 20:719-726.
16. Bentsen AH, Ansel L, Simonneaux V, Tena-Sempere M, Juul A, Mikkelsen JD. Maturation of kisspeptinergic neurons coincides with puberty onset in male rats. Peptides 2010; 31:275-283.
17. Bilban M, Ghaffari-Tabrizi N, Hintermann E, Bauer S, Molzer S, Zoratti C, et al. Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci 2004; 117:1319-1328.
18. Muir AI, Chamberlain L, Elshourbagy NA, Michalovich D, Moore DJ, Calamari A, et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem 2001; 276:28969-28975.
19. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001; 411:613-617.
20. Castellano JM, Navarro VM, Roa J, Pineda R, Sánchez-Garrido MA, García- Galiano D, et al. Alterations in hypothalamic KiSS-1 system in experimental diabetes: Early changes and functional consequences. Endocrinology 2009; 150:784-794.
21. Hauge-Evans AC, Richardson CC, Milne HM, Christie MR, Persaud SJ, Jones PM. A role for kisspeptin in islet function. Diabetologia 2006; 49:2131-2135.
22. Xu J, Kirigiti MA, Grove KL, Smith MS. Regulation of food intake and gonadotropin-releasing hormone/luteinizing hormone during lactation: Role of insulin and leptin. Endocrinology 2009; 150:4231-4240.
23. Mead EJ, Maguire JJ, Kuc RE, Davenport AP. Kisspeptins are novel potent vasoconstrictor in humans, with a discrete localization of their receptor GPR54, to atherosclerosis prone vessels. Endocrinology 2006; 148:14-147.
24. Lee JH, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 1997; 57:2384-2387.
25. Sanchez-Carbayo M, Capodieci P, Cordon-Cardo C. Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol 2003; 162:609-617. (Pubitemid 36267867)
26. Ikeguchi M, Yamaguchi K, Kaibara N. Clinical significance of the loss of KiSS-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in esophageal squamous cell carcinoma. Clin Cancer Res 2004; 10:1379-1383.
27. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27:5287-5297.
28. Khorana AA. Venous thromboembolism and prognosis in cancer. Thrombosis Res 2010; 125:490-493.
29. De Lorenzo F, Dotsenko O, Scully MF, Tymoshchuk M. The role of anticoagulation in cancer patients: Facts and figures. Anticancer Agents Med Chem 2006; 6:579-587. (Pubitemid 44697116)
30. Mousa SA. Anticoagulants in thrombosis and cancer: The missing link. Exp Rev Anticancer Ther 2: 227-233.
31. Letai A, Kuter DJ. Cancer, coagulation and anticoagulation. Oncologist 1999; 4:443-449.
32. Ornstein DL, Zacharski LR. Cancer, thrombosis, and anticoagulants. Curr Opin Pulmon Med 2000; 6:301-308.
33. Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbit by inhibiting tissue factor function. Thromb Haemost 1997; 78:1142-1149.
34. Navarro VM, Castellano JM, Fernandez-Fernanadez R, Barreiro ML, Roa J, Sanchez-Criado JE, et al. Developmental and hormonally regulated messenger ribonucleic acid expression of KiSS-1 and its putative receptor GPR54, in rat hypothalamus and potent leuteinizing hormone-releasing activity of KiSS-1 peptide. Endocrinology 2004; 145:4565-4574.
35. Davidson S, Haslett C. Davidson's principles and practice of medicine, 19th ed. Edinburgh: Churchill Livingstone; 2002.
36. Dahlback B. Blood coagulation. Lancet 2000; 355:1627-1632.
37. Colman RW. Hemostasis and thrombosis: basic principles and clinical practice, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
38. Schmaier AH. Contact activation: A revision. Thromb Haemost 1997; 78:101-107.
39. Hampton K, Preston F. ABC of clinical hematology: bleeding disorders, thrombosis, and anticoagulation. BMJ 1997; 314:10-26.
40. Norman KE. Alternative treatments for disseminated intravascular coagulation. Drug News Perspect 2004; 17:243-250.
41. Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab 2005; 90:6609-6615.
42. Swan SK, ST Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Phamacotherapy 2000; 20:756-767.
43. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs. 3, 8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol 1997; 107:105-110.
44. Levin J, Bessman JD. The inverse relation between platelet volume and platelet number. Abnormalities in hematologic disease and evidence that platelet size does not correlate with platelet age. J Lab Clin Med 1983; 101:295-307.
45. Castellano JM, Navarro VM, fernández-Fernández R, Castaño P, Malagón MM, Aguilar E, et al. Ontogeny and mechanism of action of kisspeptin on gonadotrophin-releasing hormone system of the rat. Mol Cell Endocrinol 2006; 257-258:75-83.
46. Gilaad GK, Braden M, Kevin M. Heparin induced thrombocytopenia secondary to intraperitoneal heparin exposure. Nephrol Dial Transplant 2005; 20:256-262.
47. Castelli R, Cassinerio E, Cappelini MD, Porro F, Graziadei G, Fabris F. Heparin induced thrombocytopenia: Pathogenetic, clinical, diagnostic and therapeutic aspects. Cardiovasc Hematol Disord Drug Target 2007; 7:153-161.
48. Henk M, Verheul W, Pinedo1 HM. The importance of platelet counts and their contents in cancer. Clin Cancer Res 2003; 9:3219-3221.
49. Schafer AI, Loscalzo J. Thrombosis and hemorrhage. Hagerstown, MD: Lippincott Williams & Wilkins; 2003.
50. Jurasz P, Alonso-Escolano D, RadomskiMW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 2004; 143:819-826.
51. Erpenbeck L, Schön MP. Deadly allies: The fatal interplay between platelets and metastasizing cancer cells. Blood 2010; 115:3427-3436.
52. Masui T, Doi R, Mori T, Toyoda E, Koizumi M, Kami K, et al. Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochem Biophys Res Commun 2004; 315:85-92.
53. SanchezCarbayo M, Capodieci P, Cordon-Cardo C. Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol 2003; 162:609-617. (Pubitemid 36267867)
54. Hesling C, D'incan M, Mansard S, Franck F, Corbin-Duval A, Chèvenet C, et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 2004; 150:761-767.